Literature DB >> 22507272

Survivin knockdown increased anti-cancer effects of (-)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells.

Md Motarab Hossain1, Naren L Banik, Swapan K Ray.   

Abstract

Neuroblastoma is a solid tumor that mostly occurs in children. Malignant neuroblastomas have poor prognosis because conventional chemotherapeutic agents are hardly effective. Survivin, which is highly expressed in some malignant neuroblastomas, plays a significant role in inhibiting differentiation and apoptosis and promoting cell proliferation, invasion, and angiogenesis. We examined consequences of survivin knockdown by survivin short hairpin RNA (shRNA) plasmid and then treatment with (-)-epigallocatechin-3-gallate (EGCG), a green tea flavonoid, in malignant neuroblastoma cells. Our Western blotting and laser scanning confocal immunofluorescence microscopy showed that survivin was highly expressed in malignant neuroblastoma SK-N-BE2 and SH-SY5Y cell lines and slightly in SK-N-DZ cell line. Expression of survivin was very faint in malignant neuroblastoma IMR32 cell line. We transfected SK-N-BE2 and SH-SY-5Y cells with survivin shRNA, treated with EGCG, and confirmed knockdown of survivin at mRNA and protein levels. Survivin knockdown induced morphological features of neuronal differentiation, as we observed following in situ methylene blue staining. Combination of survivin shRNA and EGCG promoted neuronal differentiation biochemically by increases in the expression of NFP, NSE, and e-cadherin and also decreases in the expression of Notch-1, ID2, hTERT, and PCNA. Our in situ Wright staining and Annexin V-FITC/PI staining showed that combination therapy was highly effective in inducing, respectively, morphological and biochemical features of apoptosis. Apoptosis occurred with activation of caspase-8 and cleavage of Bid to tBid, increase in Bax:Bcl-2 ratio, mitochondrial release of cytochrome c, and increases in the expression and activity of calpain and caspase-3. Combination therapy decreased migration of cells through matrigel and inhibited proliferative (p-Akt and NF-κB), invasive (MMP-2 and MMP-9), and angiogenic (VEGF and b-FGF) factors. Also, in vitro network formation ability of cells was significantly inhibited by survivin silencing and completely by combination of survivin silencing and EGCG treatment. Collectively, survivin silencing potentiated anti-cancer effects of EGCG in human malignant neuroblastoma cells having survivin overexpression.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22507272      PMCID: PMC3374045          DOI: 10.1016/j.yexcr.2012.03.033

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  39 in total

Review 1.  The case for survivin as a regulator of microtubule dynamics and cell-death decisions.

Authors:  Dario C Altieri
Journal:  Curr Opin Cell Biol       Date:  2006-08-24       Impact factor: 8.382

2.  Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.

Authors:  Christopher E Pelloski; E Lin; Li Zhang; W K Alfred Yung; Howard Colman; Juinn-Lin Liu; Shaio Y Woo; Amy B Heimberger; Dima Suki; Michael Prados; Susan Chang; Fredrick G Barker; Gregory N Fuller; Kenneth D Aldape
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

3.  Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis.

Authors:  Zhiyin Song; Xuebiao Yao; Mian Wu
Journal:  J Biol Chem       Date:  2003-03-26       Impact factor: 5.157

Review 4.  Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy.

Authors:  Subbareddy Maddika; Sudharsana Rao Ande; Soumya Panigrahi; Ted Paranjothy; Kazimierz Weglarczyk; Anne Zuse; Mehdi Eshraghi; Kamala D Manda; Emilia Wiechec; Marek Los
Journal:  Drug Resist Updat       Date:  2007-02-14       Impact factor: 18.500

5.  High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma.

Authors:  A Islam; H Kageyama; N Takada; T Kawamoto; H Takayasu; E Isogai; M Ohira; K Hashizume; H Kobayashi; Y Kaneko; A Nakagawara
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

6.  Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.

Authors:  I A Siddiqui; A Malik; V M Adhami; M Asim; B B Hafeez; S Sarfaraz; H Mukhtar
Journal:  Oncogene       Date:  2007-11-12       Impact factor: 9.867

Review 7.  Targeting survivin in cancer therapy.

Authors:  Marzia Pennati; Marco Folini; Nadia Zaffaroni
Journal:  Expert Opin Ther Targets       Date:  2008-04       Impact factor: 6.902

Review 8.  Survivin, cancer networks and pathway-directed drug discovery.

Authors:  Dario C Altieri
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

9.  EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells.

Authors:  Y D Jung; M S Kim; B A Shin; K O Chay; B W Ahn; W Liu; C D Bucana; G E Gallick; L M Ellis
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

10.  Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

Authors:  Anthony W Tolcher; Alain Mita; Lionel D Lewis; Christopher R Garrett; Elizabeth Till; Adil I Daud; Amita Patnaik; Kyri Papadopoulos; Chris Takimoto; Pamela Bartels; Anne Keating; Scott Antonia
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 50.717

View more
  14 in total

1.  Downregulation of survivin inhibits proliferation and migration of human gastric carcinoma cells.

Authors:  Yandong Li; Yongli Zhou; Jianyun Zheng; Chunyan Niu; Bing Liu; Meini Wang; Hangrong Fang; Chuan Hou
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 2.  Recent advances in delivery of drug-nucleic acid combinations for cancer treatment.

Authors:  Jing Li; Yan Wang; Yu Zhu; David Oupický
Journal:  J Control Release       Date:  2013-04-25       Impact factor: 9.776

3.  Going Green: The Role of the Green Tea Component EGCG in Chemoprevention.

Authors:  Laura Schramm
Journal:  J Carcinog Mutagen       Date:  2013-05-20

4.  miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo.

Authors:  Mrinmay Chakrabarti; Naren L Banik; Swapan K Ray
Journal:  Exp Cell Res       Date:  2013-04-03       Impact factor: 3.905

5.  Downregulation of survivin by siRNA inhibits invasion and promotes apoptosis in neuroblastoma SH-SY5Y cells.

Authors:  L Zhang; H Liang; W Cao; R Xu; X L Ju
Journal:  Braz J Med Biol Res       Date:  2014-05-23       Impact factor: 2.590

6.  Epigallocatechin-3-gallate enhances the therapeutic effects of leptomycin B on human lung cancer a549 cells.

Authors:  Meghan M Cromie; Weimin Gao
Journal:  Oxid Med Cell Longev       Date:  2015-04-01       Impact factor: 6.543

7.  Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.

Authors:  Hayat Zaatiti; Jad Abdallah; Zeina Nasr; George Khazen; Anthony Sandler; Tamara J Abou-Antoun
Journal:  Int J Oncol       Date:  2018-01-04       Impact factor: 5.650

8.  EWS Knockdown and Taxifolin Treatment Induced Differentiation and Removed DNA Methylation from p53 Promoter to Promote Expression of Puma and Noxa for Apoptosis in Ewing's Sarcoma.

Authors:  Mohammad Motarab Hossain; Swapan Kumar Ray
Journal:  J Cancer Ther       Date:  2014-10-28

Review 9.  The twisted survivin connection to angiogenesis.

Authors:  C Sanhueza; S Wehinger; J Castillo Bennett; M Valenzuela; G I Owen; A F G Quest
Journal:  Mol Cancer       Date:  2015-11-19       Impact factor: 27.401

10.  APE1 deficiency promotes cellular senescence and premature aging features.

Authors:  Mengxia Li; Xiao Yang; Xianfeng Lu; Nan Dai; Shiheng Zhang; Yi Cheng; Lei Zhang; Yuxin Yang; Yie Liu; Zhenzhou Yang; Dong Wang; David M Wilson
Journal:  Nucleic Acids Res       Date:  2018-06-20       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.